business development

Addex is pioneering the industrialization of allosteric drug discovery and development. In doing so the company has developed a portfolio of proprietary tools that make up the allosteric modulator discovery and development platform. The platform has proven itself to be broadly applicable and has generated many molecules for indications with significant commercial potential in our three core therapeutic areas: central nervous system (CNS), metabolic disorders and inflammation. Indeed, the Addex platform’s capabilities have generated partnerships with two of the largest and most respected companies in the business: Merck & Co., Inc. and Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson & Johnson company.

Because the Addex platform is scalable and capable of producing a growing stream of new projects, partnering is an important way to create shareholder value in the short term, while, at the same time, reducing risk associated with individual molecules. Addex aims to partner with large companies that have the expertise and resources to maximize our chances for success. In other words, we will seek experienced partners who know the best way to advance certain products through development and surmount regulatory hurdles in order to bring new medicines to patients as quickly as possible.

Part of our partnering strategy is to seek co-development and co-promotion rights in order to continue to grow our organization by benefiting from our partners’ competencies even as we reduce the risk and costs for developing our products. This allows us to retain more of the upside than straight outlicensing would and build up our own revenue stream from product sales. Most importantly, our partnering strategy allows us to leverage our platform technology to generate near-term revenues while at the same time reducing our dependence on the near-term performance of any single project in our pipeline.